Market Overview

TickerTags Data Shows Drug Price Debate Still Trending

Share:
TickerTags Data Shows Drug Price Debate Still Trending

Hillary Clinton’s September 21 Twitter criticism of Martin Shkreli following a drastic Daraprim price hike set off a whirlwind of debate over whether or not the government should step in with stricter regulations on drug prices.

Understandably, these debates have spooked biotech investors, and the SPDR S&P Biotech (ETF) (NYSE: XBI) is now down 42.8 percent in the past six months.

It’s been more than four months since Clinton’s original tweet, but the latest data from Ticker Tags indicates that the social media universe hasn’t forgotten about the issue. Ticker Tags monitors social media sites to identify trends by searching for words or phrases that are found together in social media content, such as tweets.

Related Link: Google Cardboard's Social Media Buzz Skyrocketing; Yahoo's Tumblr Having Bad Time

According to the data, instances of tweets containing “Hillary Clinton+drug” and “price+drug” remain elevated as the primary season kicked off this week.

With prescription drug pricing still trending on social media, it won’t be surprising to see the topic continue to come up throughout the remainder of the election year. Biotech investors should be prepared for additional headline risk.

Disclosure: the author holds no position in the stocks mentioned.

 

Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech News Education Politics Top Stories Tech Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com